<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956590</url>
  </required_header>
  <id_info>
    <org_study_id>PHN DO IT!</org_study_id>
    <nct_id>NCT02956590</nct_id>
  </id_info>
  <brief_title>Dyslipidemia of Obesity Intervention in Teens</brief_title>
  <acronym>DO IT!</acronym>
  <official_title>Dyslipidemia of Obesity Intervention in Teens Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthCore-NERI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthCore-NERI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial of pitavastatin will determine efficacy and safety in this high risk population&#xD;
      and provide evidence for clinicians to target this treatable risk factor to achieve an impact&#xD;
      on early atherosclerosis, and potentially achieve primary prevention of adult cardiovascular&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled clinical trial of pitavastatin for 2 years&#xD;
      comparing the effect of study drug versus placebo on vascular measures in at least 354&#xD;
      adolescents with excess adiposity and CDO (defined as high non-HDL-C + high TG/HDL-C ratio or&#xD;
      low HDL-C). Enrollment will take place over 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effect of pitavastatin versus placebo on vascular measures in at least 354 obese adolescents with combined dyslipidemia of obesity (CDO)</measure>
    <time_frame>2 years</time_frame>
    <description>Pulse wave velocity (PWV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on vascular measures in obese adolescents with combined dyslipidemia of obesity (CDO)</measure>
    <time_frame>2 years</time_frame>
    <description>carotid intima media thickness (CIMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on vascular measures in at least 354 obese adolescents with combined dyslipidemia of obesity</measure>
    <time_frame>2 years</time_frame>
    <description>carotid artery stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on Standard Fasting Lipid Profile (FLP)</measure>
    <time_frame>2 years</time_frame>
    <description>Change in time in standard fasting lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on lipid measures</measure>
    <time_frame>2 years</time_frame>
    <description>Change in time in apolipoproteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on Nuclear magnetic resonance (NMR) Spectroscopy Lipoprotein Particle Assessment</measure>
    <time_frame>2 years</time_frame>
    <description>Change in time in NMR Spectroscopy Lipoprotein Particle Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on composite outcome of Number of Participants With Abnormal Laboratory Values and/or Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Number of abnormal (yes/no) lab values based on Liver function tests (ALT, AST); creatine kinase (CK), muscle symptoms; markers of glycemic control/development of diabetes (fasting plasma glucose, HgbA1c) and change in surrogate markers of insulin sensitivity (fasting insulin, C-peptide, Homeostatic model assessment Insulin resistance (HOMA-IR), 1/insulin, QUICKI); height velocity (change in height z score) and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on prevalence of adverse events.</measure>
    <time_frame>2 years</time_frame>
    <description>Number of adverse events and other subject-reported symptoms (including neurocognitive and depressive symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on prevalence of abnormal Liver function tests (ALT, AST)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of abnormal (yes/no) lab values based on Liver function tests (ALT, AST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on prevalence of abnormal creatinine kinase (CK) tests</measure>
    <time_frame>2 years</time_frame>
    <description>Number of abnormal (yes/no) lab values based on creatinine kinase (CK) tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on composite outcome of markers of glycemic control/development of diabetes</measure>
    <time_frame>2 years</time_frame>
    <description>Number of abnormal (yes/no) lab values based on markers of glycemic control/development of diabetes (fasting plasma glucose, HgbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on composite outcome of abnormal change in surrogate markers of insulin sensitivity</measure>
    <time_frame>2 years</time_frame>
    <description>Number of abnormal (yes/no) lab values based on change in surrogate markers of insulin sensitivity (fasting insulin, C-peptide, HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of pitavastatin versus placebo on prevalence of abnormal changes in height</measure>
    <time_frame>2 years</time_frame>
    <description>Number of abnormal (yes/no) values based on change in height in time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Statin</description>
    <arm_group_label>Pitavastatin</arm_group_label>
    <other_name>Livalo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Boys and girls aged 10 to 19 years (with 2-year availability for study participation)&#xD;
&#xD;
          -  BMI ≥85th percentile (using CDC BMI charts)&#xD;
&#xD;
          -  Fasting lipid profile x2 each with all of the following:&#xD;
&#xD;
               -  LDL-C &lt;160 mg/dL and ≥90 mg/dL, and&#xD;
&#xD;
               -  TG &lt;500 mg/dL, and&#xD;
&#xD;
               -  TG/HDL-C ratio ≥2.5 or HDL-C &lt;45 mg/dL for boys or HDL-C &lt;50 mg/dL for girls, and&#xD;
&#xD;
               -  non-HDL-C ≥120 mg/dL&#xD;
&#xD;
          -  Participant consent, or parental/guardian consent and participant assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of lipid lowering medication, growth hormone, systemic corticosteroids,&#xD;
             cyclosporine, protease inhibitors, erythromycin, rifampin, colchicine, warfarin,&#xD;
             second generation psychotropic drugs, oral isotretinoin; stable doses of stimulant or&#xD;
             antidepressant therapy and antihypertensive medications will be accepted&#xD;
&#xD;
          -  Known allergy or hypersensitivity to statin&#xD;
&#xD;
          -  Patients who have had bariatric surgery or plan to have bariatric surgery during the&#xD;
             trial&#xD;
&#xD;
          -  Female who is pregnant, plans to become pregnant or is sexually active without&#xD;
             contraception&#xD;
&#xD;
          -  Uncontrolled stage 2 hypertension (systolic or diastolic blood pressure ≥95th&#xD;
             percentile for age, sex and height percentile + 12 mmHg or ≥140/90, whichever is lower&#xD;
             for participants &lt;13 years of age; ≥140/90 for participants ≥13 years of age)&#xD;
             confirmed after an appropriate evaluation&#xD;
&#xD;
          -  Diabetes (type 1 or type 2) by American Diabetes Association criteria (fasting glucose&#xD;
             ≥126 mg/dL, HbA1c ≥6.5%, random glucose ≥200 mg/dL, or 2-hour oral glucose tolerance&#xD;
             testing glucose ≥200 mg/dL)&#xD;
&#xD;
          -  Use of insulin sensitizing therapy&#xD;
&#xD;
          -  Known renal insufficiency (known chronic renal disease, estimated GFR &lt;60&#xD;
             mL/min/1.73m2 at screening)&#xD;
&#xD;
          -  Uncontrolled thyroid disease (TSH at screening &gt;1.5x upper limit of normal, clinical&#xD;
             or other laboratory evidence of hypothyroidism, or thyroid hormone therapy that has&#xD;
             not been stable for 6 weeks prior to screening)&#xD;
&#xD;
          -  Proteinuria suggestive of renal disease (more than trace together with an elevated&#xD;
             urine protein:creatinine ratio as per local lab)&#xD;
&#xD;
          -  Syndromic patients or patients with neurocognitive delay precluding adherence with&#xD;
             study drug&#xD;
&#xD;
          -  Liver disease other than non-alcoholic fatty liver disease (NAFLD) either diagnosed or&#xD;
             suggested by alanine aminotransferase (ALT) ≥ 40 U/L, or severe NAFLD indicated by ALT&#xD;
             ≥ 200 U/L&#xD;
&#xD;
          -  Unexplained persistent elevated creatine kinase (CK) level &gt;3x upper limit of normal&#xD;
&#xD;
          -  Plans to leave the geographic area before completion of the anticipated 2 years of&#xD;
             trial participation&#xD;
&#xD;
          -  Any unstable medical or emotional condition or chronic disease that would preclude&#xD;
             following the protocol or impact valid vascular measurement&#xD;
&#xD;
          -  Admits to current smoking, current alcohol consumption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nemours/Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5g 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dyslipidemia</keyword>
  <keyword>obesity</keyword>
  <keyword>pitavastatin</keyword>
  <keyword>lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

